Managing cardiovascular risk factors in patients with chronic kidney disease: Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Managing cardiovascular risk factors in patients with chronic kidney disease : Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort. / Freese Ballegaard, Ellen Linnea; Carlson, Nicholas; Buus Jørgensen, Morten; Sørensen, Ida Maria Hjelm; Trankjær, Helene; Almarsdóttir, Anna Birna; Bro, Susanne; Feldt-Rasmussen, Bo; Kamper, Anne Lise; for The Copenhagen CKD Cohort Study Group.

In: Clinical Kidney Journal, Vol. 17, No. 7, sfae158, 2024.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Freese Ballegaard, EL, Carlson, N, Buus Jørgensen, M, Sørensen, IMH, Trankjær, H, Almarsdóttir, AB, Bro, S, Feldt-Rasmussen, B, Kamper, AL & for The Copenhagen CKD Cohort Study Group 2024, 'Managing cardiovascular risk factors in patients with chronic kidney disease: Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort', Clinical Kidney Journal, vol. 17, no. 7, sfae158. https://doi.org/10.1093/ckj/sfae158

APA

Freese Ballegaard, E. L., Carlson, N., Buus Jørgensen, M., Sørensen, I. M. H., Trankjær, H., Almarsdóttir, A. B., Bro, S., Feldt-Rasmussen, B., Kamper, A. L., & for The Copenhagen CKD Cohort Study Group (2024). Managing cardiovascular risk factors in patients with chronic kidney disease: Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort. Clinical Kidney Journal, 17(7), [sfae158]. https://doi.org/10.1093/ckj/sfae158

Vancouver

Freese Ballegaard EL, Carlson N, Buus Jørgensen M, Sørensen IMH, Trankjær H, Almarsdóttir AB et al. Managing cardiovascular risk factors in patients with chronic kidney disease: Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort. Clinical Kidney Journal. 2024;17(7). sfae158. https://doi.org/10.1093/ckj/sfae158

Author

Freese Ballegaard, Ellen Linnea ; Carlson, Nicholas ; Buus Jørgensen, Morten ; Sørensen, Ida Maria Hjelm ; Trankjær, Helene ; Almarsdóttir, Anna Birna ; Bro, Susanne ; Feldt-Rasmussen, Bo ; Kamper, Anne Lise ; for The Copenhagen CKD Cohort Study Group. / Managing cardiovascular risk factors in patients with chronic kidney disease : Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort. In: Clinical Kidney Journal. 2024 ; Vol. 17, No. 7.

Bibtex

@article{9994a11a32714a00b542a6da93c49bb2,
title = "Managing cardiovascular risk factors in patients with chronic kidney disease: Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort",
abstract = "Background: Although cardiovascular morbidity and mortality are substantial in patients with chronic kidney disease (CKD), guideline-directed treatment of cardiovascular risk factors remains a challenge. Methods: Observational, cross-sectional study including patients aged 30-75 years with CKD stage 1-5 without kidney replacement therapy from a tertiary hospital outpatient clinic. Data were obtained through patient interview, clinical examination, biochemical work-up, and evaluation of medical records and prescription redemptions. Guideline-directed treatment was evaluated as pharmacological interventions: Antihypertensive and lipid-lowering therapy including adverse effects and adherence estimated as medication possession ratio (MPR); and non-pharmacological interventions: smoking status, alcohol consumption, body mass index (BMI), and physical activity. Results: The cohort comprised 741 patients, mean age 58 years, 61.4% male, 50.6% CKD stage 3, 61.0% office blood pressure ≤140/90 mmHg. Antihypertensives were prescribed to 87.0%, median number of medications 2 (IQR 1;3), 70.1% received renin-Angiotensin system inhibition, 25.9% reported adverse effects. Non-Adherence (MPR < 80%) was present in 23.4% and associated with elevated blood pressure (OR 1.53 (95% CI 1.03;2.27)) and increased urinary albumin excretion, P < 0.001. Lipid-lowering treatment was prescribed to 54.0% of eligible patients, 11.1% reported adverse effects, and 28.5% were non-Adherent, which was associated with higher LDL cholesterol, P = 0.036. Overall, 19.2% were current smokers, 16.7% overconsumed alcohol according to Danish health authority recommendations 69.3% had BMI ≥ 25 kg/m2, and 38.3% were physically active <4 hours/week. Among patients prescribed antihypertensives, 51.9% reported having received advice on non-pharmacological interventions. Conclusions: Improved management of cardiovascular risk in patients with CKD entails intensified medical treatment and increased focus on patient adherence and non-pharmacological interventions. ",
keywords = "adherence, blood pressure, cardiovascular, chronic kidney disease, dyslipidemia",
author = "{Freese Ballegaard}, {Ellen Linnea} and Nicholas Carlson and {Buus J{\o}rgensen}, Morten and S{\o}rensen, {Ida Maria Hjelm} and Helene Trankj{\ae}r and Almarsd{\'o}ttir, {Anna Birna} and Susanne Bro and Bo Feldt-Rasmussen and Kamper, {Anne Lise} and {for The Copenhagen CKD Cohort Study Group}",
note = "Publisher Copyright: {\textcopyright} 2024 The Author(s).",
year = "2024",
doi = "10.1093/ckj/sfae158",
language = "English",
volume = "17",
journal = "Clinical Kidney Journal",
issn = "2048-8505",
publisher = "European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)",
number = "7",

}

RIS

TY - JOUR

T1 - Managing cardiovascular risk factors in patients with chronic kidney disease

T2 - Pharmacological and non-pharmacological interventions in the Copenhagen CKD Cohort

AU - Freese Ballegaard, Ellen Linnea

AU - Carlson, Nicholas

AU - Buus Jørgensen, Morten

AU - Sørensen, Ida Maria Hjelm

AU - Trankjær, Helene

AU - Almarsdóttir, Anna Birna

AU - Bro, Susanne

AU - Feldt-Rasmussen, Bo

AU - Kamper, Anne Lise

AU - for The Copenhagen CKD Cohort Study Group

N1 - Publisher Copyright: © 2024 The Author(s).

PY - 2024

Y1 - 2024

N2 - Background: Although cardiovascular morbidity and mortality are substantial in patients with chronic kidney disease (CKD), guideline-directed treatment of cardiovascular risk factors remains a challenge. Methods: Observational, cross-sectional study including patients aged 30-75 years with CKD stage 1-5 without kidney replacement therapy from a tertiary hospital outpatient clinic. Data were obtained through patient interview, clinical examination, biochemical work-up, and evaluation of medical records and prescription redemptions. Guideline-directed treatment was evaluated as pharmacological interventions: Antihypertensive and lipid-lowering therapy including adverse effects and adherence estimated as medication possession ratio (MPR); and non-pharmacological interventions: smoking status, alcohol consumption, body mass index (BMI), and physical activity. Results: The cohort comprised 741 patients, mean age 58 years, 61.4% male, 50.6% CKD stage 3, 61.0% office blood pressure ≤140/90 mmHg. Antihypertensives were prescribed to 87.0%, median number of medications 2 (IQR 1;3), 70.1% received renin-Angiotensin system inhibition, 25.9% reported adverse effects. Non-Adherence (MPR < 80%) was present in 23.4% and associated with elevated blood pressure (OR 1.53 (95% CI 1.03;2.27)) and increased urinary albumin excretion, P < 0.001. Lipid-lowering treatment was prescribed to 54.0% of eligible patients, 11.1% reported adverse effects, and 28.5% were non-Adherent, which was associated with higher LDL cholesterol, P = 0.036. Overall, 19.2% were current smokers, 16.7% overconsumed alcohol according to Danish health authority recommendations 69.3% had BMI ≥ 25 kg/m2, and 38.3% were physically active <4 hours/week. Among patients prescribed antihypertensives, 51.9% reported having received advice on non-pharmacological interventions. Conclusions: Improved management of cardiovascular risk in patients with CKD entails intensified medical treatment and increased focus on patient adherence and non-pharmacological interventions.

AB - Background: Although cardiovascular morbidity and mortality are substantial in patients with chronic kidney disease (CKD), guideline-directed treatment of cardiovascular risk factors remains a challenge. Methods: Observational, cross-sectional study including patients aged 30-75 years with CKD stage 1-5 without kidney replacement therapy from a tertiary hospital outpatient clinic. Data were obtained through patient interview, clinical examination, biochemical work-up, and evaluation of medical records and prescription redemptions. Guideline-directed treatment was evaluated as pharmacological interventions: Antihypertensive and lipid-lowering therapy including adverse effects and adherence estimated as medication possession ratio (MPR); and non-pharmacological interventions: smoking status, alcohol consumption, body mass index (BMI), and physical activity. Results: The cohort comprised 741 patients, mean age 58 years, 61.4% male, 50.6% CKD stage 3, 61.0% office blood pressure ≤140/90 mmHg. Antihypertensives were prescribed to 87.0%, median number of medications 2 (IQR 1;3), 70.1% received renin-Angiotensin system inhibition, 25.9% reported adverse effects. Non-Adherence (MPR < 80%) was present in 23.4% and associated with elevated blood pressure (OR 1.53 (95% CI 1.03;2.27)) and increased urinary albumin excretion, P < 0.001. Lipid-lowering treatment was prescribed to 54.0% of eligible patients, 11.1% reported adverse effects, and 28.5% were non-Adherent, which was associated with higher LDL cholesterol, P = 0.036. Overall, 19.2% were current smokers, 16.7% overconsumed alcohol according to Danish health authority recommendations 69.3% had BMI ≥ 25 kg/m2, and 38.3% were physically active <4 hours/week. Among patients prescribed antihypertensives, 51.9% reported having received advice on non-pharmacological interventions. Conclusions: Improved management of cardiovascular risk in patients with CKD entails intensified medical treatment and increased focus on patient adherence and non-pharmacological interventions.

KW - adherence

KW - blood pressure

KW - cardiovascular

KW - chronic kidney disease

KW - dyslipidemia

U2 - 10.1093/ckj/sfae158

DO - 10.1093/ckj/sfae158

M3 - Journal article

C2 - 38979108

AN - SCOPUS:85198664988

VL - 17

JO - Clinical Kidney Journal

JF - Clinical Kidney Journal

SN - 2048-8505

IS - 7

M1 - sfae158

ER -

ID: 399106347